전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-3 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved1,016 programs
AntibodyLimited DatastaleJanssenPhase 3

Daratumumab (CT-P44, CT-P44(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RefractoryorRelapsedMultipleMyel+1
Trials 1Status Recruiting
CGTLimited DatastaleCARsgen Therapeutics Co., Ltd.Preclinical

CT0590 CAR T Cells (CT0590 CAR T Cells)

Relapsed and/or Refractory Multiple Myeloma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleMEI HENGPhase 1

CT0991 CAR-T cells infusicn (CT0991 CAR-T cells infusicn)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai Cell Therapy Research …Phase 2

CTLA-4/PD-1 antibodies expressing mesoCAR-T (CTLA-4/PD-1 antibodies expressing mesoCAR-T)

Advanced Solid Tumor · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleThe First Affiliated Hospital o…Phase 1

CXCR4 CCR9 CAR-T (CXCR4 CCR9 CAR-T)

Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleShen FengPhase 2

Cadonilimab+Gem/Cis (Cadonilimab+Gem/Cis)

Intrahepatic Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma

#IntrahepaticCholangiocarcinoma#Antibody#Phase2#monoclonal-antibody#Shen
Trials 1Status Active
AntibodyLimited DatastaleShanghai General Hospital, Shan…Phase 2

Cadonilimab+S-1or Capecitabine (Cadonilimab+S-1or Capecitabine)

Pancreatic Neoplasms · Pancreatic Neoplasms

#PancreaticNeoplasms#Antibody#Phase2#monoclonal-antibody#Shanghai
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab and Bevacizumab (Camrelizumab and Bevacizumab)

Recurrent Glioblastoma · Recurrent Glioblastoma

#RecurrentGlioblastoma#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Discontinued
AntibodyLimited DatastaleSanofiPhase 3

Caplacizumab (Caplacizumab)

Acquired Thrombotic Thrombocytopenic Purpura · Acquired Thrombotic Thrombocytopenic Pur

#AcquiredThromboticThrombocytopen#Antibody#Phase3#monoclonal-antibody#Sanofi
Trials 1Status Active
AntibodyLimited DatastaleThe Netherlands Cancer InstitutePhase 2

atezolizumab (Tecentriq, Carbo/cyclo + atezolizumab)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
CGTLimited DatastaleCaribou Biosciences, Inc.Preclinical

Caribou-sponsored investigational therapy (Caribou-sponsored investigational therapy)

Lymphoma, Non-Hodgkin; Relapsed Non-Hodgkin Lymphoma · FRα

#FR#CGT#Preclinical#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleFudan UniversityPhase 2

Carrelizumab (Carrelizumab)

Breast Neoplasm; Breast Cancer · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#BreastNeoplasm+2
Trials 1Status Recruiting
CGTLimited DatastaleMiltenyi Biotec, Inc.Phase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous))

B-Cell Lymphoma; B Acute Lymphoblastic Leukemia · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleJennifer Crombie, MDPhase 2

Chimeric Antigen Receptor (CAR, Chimeric Antigen Receptor, Chimeric Antigen Receptor (CAR) Therapy Infusion)

Primary Mediastinal Large B-cell Lymphoma (PMBCL); Primary Mediastinal Large B Cell Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleO&D BioTech Group CO., LimitedPhase 1

Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D (Chimeric antigen receptor T cell O&D-001 injection targeting BCMA and GPRC5D)

Relapsed or Refractory Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNelson HamerschlakPhase 1

Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0 (Chimeric antigen receptor T cells to be implemented in a "3 + 3" design on day 0)

Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 1

Cibisatamab (Cibisatamab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase1#monoclonal-antibody#Hoffmann-La
Trials 1Status Discontinued
CGTLimited DatastaleSuzhou Immunofoco Biotechnology…Phase 1

Claudin 18.2 CAR-T (Claudin 18.2 CAR-T)

Gastric Cancer; Pancreatic Cancer · Gastric Cancer

#GastricCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleShenzhen University General Hos…Preclinical

Claudin18.2 CAR-T cells (Claudin18.2 CAR-T cells)

Advanced Pancreatic Carcinoma; Advanced Gastric Carcinoma · Advanced Pancreatic Carcinoma

#AdvancedPancreaticCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleSecond Affiliated Hospital of G…Phase 1

Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells (Claudin6, GPC3, Mesothelin, or AXL targeting CAR-NK cells)

Stage IV Ovarian Cancer; Testis Cancer, Refractory · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting

30 / 51 pages

← PreviousNext →